Myopia Management Lenses: What Optical Practices Should Verify
Correcting blurred distance vision and slowing myopia progression are different goals. Optical practices should identify the exact product and its evidence before describing a spectacle lens as a myopia-control treatment. Ordinary customization or freeform manufacturing alone does not establish that indication.
Distinguish prescription correction from myopia control
A lens that corrects a myopic prescription should not automatically be advertised as slowing progression. Product-specific indications, study populations and fitting instructions matter. Do not transfer the evidence for one branded design to another design or to all custom lenses.
Check the product’s authorized indication
In September 2025, the FDA authorized Essilor® Stellest® spectacle lenses to correct myopia, with or without astigmatism, and slow its progression in children aged 6–12 when treatment starts. This is a product-specific authorization. Read the FDA announcement.
This example does not establish MIALAB availability. Confirm the current label, prescription limits, ordering channel and supply arrangements for the exact product before recommending or ordering it.
Follow the prescribing clinician’s management plan
Patient selection, treatment choice and monitoring belong with the qualified eyecare professional. The lab order should reflect that clinician’s instructions and the manufacturer’s requirements. A general article cannot determine which approach is appropriate for an individual child.
Do not substitute an ordinary progressive or customized single vision design for a prescribed myopia-management product without the prescriber’s review.
Confirm fitting and ordering requirements
- Identify the exact product and current labeling.
- Confirm patient eligibility and the prescription with the clinician.
- Check the required frame, measurements and fitting instructions.
- Verify material, treatment and supply availability.
- Provide the manufacturer’s wear and care instructions.
- Keep follow-up arrangements with the treating practice clear.
Explain benefits without promising an individual outcome
Use the evidence for the selected treatment and explain its limits. Do not promise that any lens will stop progression or that manufacturing precision alone proves a clinical benefit.
Contact MIALAB to discuss a specific prescription lens order and confirm what the lab can supply. Clinical treatment decisions remain with the patient’s eyecare professional.
